源自患者的肿瘤类器官用于模拟胃癌的药物反应。
Patient-derived tumor organoids to model drug response in gastric cancer.
作者信息
Vistoso Monreal Anette, Zhao Hua, Sedghizadeh Parish P, Lin De-Chen
机构信息
Department of Diagnostic Sciences, Anesthesia & Emergency Medicine, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
出版信息
Cell Rep Med. 2024 Jul 16;5(7):101650. doi: 10.1016/j.xcrm.2024.101650.
Abstract
Gastric cancer poses diverse treatment challenges due to its high tumor heterogeneity. Through the use of patient-derived tumor organoid (PDO) models, new research has identified genes and molecular signatures that are predictive of chemotherapeutic response, providing valuable insights for clinical management and translational advancements.
摘要
由于胃癌具有高度的肿瘤异质性，因此带来了多种治疗挑战。通过使用患者来源的肿瘤类器官（PDO）模型，新的研究已经确定了可预测化疗反应的基因和分子特征，为临床管理和转化进展提供了有价值的见解。
相似文献
1
Patient-derived tumor organoids to model drug response in gastric cancer.
Cell Rep Med. 2024 Jul 16;5(7):101650. doi: 10.1016/j.xcrm.2024.101650.
2
Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Ann Surg Oncol. 2018 Sep;25(9):2767-2775. doi: 10.1245/s10434-018-6662-8. Epub 2018 Jul 12.
3
An Organoid-Based Preclinical Model of Human Gastric Cancer.
Cell Mol Gastroenterol Hepatol. 2019;7(1):161-184. doi: 10.1016/j.jcmgh.2018.09.008. Epub 2018 Sep 20.
4
Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.
Cell Rep Med. 2024 Jul 16;5(7):101627. doi: 10.1016/j.xcrm.2024.101627. Epub 2024 Jul 3.
5
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Biomed Pharmacother. 2023 Jul;163:114751. doi: 10.1016/j.biopha.2023.114751. Epub 2023 Apr 26.
6
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.
7
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Front Endocrinol (Lausanne). 2021 Mar 11;12:627819. doi: 10.3389/fendo.2021.627819. eCollection 2021.
8
Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.
J Cancer Res Clin Oncol. 2019 Nov;145(11):2637-2647. doi: 10.1007/s00432-019-03004-z. Epub 2019 Oct 9.
9
Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.
J Transl Med. 2024 Aug 12;22(1):754. doi: 10.1186/s12967-024-05512-0.
10
Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
ACS Biomater Sci Eng. 2022 Aug 8;8(8):3515-3525. doi: 10.1021/acsbiomaterials.2c00354. Epub 2022 Jun 13.
引用本文的文献
1
Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine.
Mol Diagn Ther. 2025 Sep 4. doi: 10.1007/s40291-025-00808-3.
2
Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.
Endocrine. 2025 Apr 30. doi: 10.1007/s12020-025-04240-9.
3
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.
Front Mol Biosci. 2025 Jan 15;12:1531175. doi: 10.3389/fmolb.2025.1531175. eCollection 2025.
本文引用的文献
1
Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.
Cell Rep Med. 2024 Jul 16;5(7):101627. doi: 10.1016/j.xcrm.2024.101627. Epub 2024 Jul 3.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Targeting CAFs to overcome anticancer therapeutic resistance.
Trends Cancer. 2022 Jul;8(7):527-555. doi: 10.1016/j.trecan.2022.03.001. Epub 2022 Mar 21.
4
Applications of Organoids for Cancer Biology and Precision Medicine.
Nat Cancer. 2020 Aug;1(8):761-773. doi: 10.1038/s43018-020-0102-y. Epub 2020 Aug 18.
5
An Organoid-Based Preclinical Model of Human Gastric Cancer.
Cell Mol Gastroenterol Hepatol. 2019;7(1):161-184. doi: 10.1016/j.jcmgh.2018.09.008. Epub 2018 Sep 20.
6
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.
7
Human gastric cancer modelling using organoids.
Gut. 2019 Feb;68(2):207-217. doi: 10.1136/gutjnl-2017-314549. Epub 2018 Apr 27.
8
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23.
9
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531.
10
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.
Acta Pathol Microbiol Scand. 1965;64:31-49. doi: 10.1111/apm.1965.64.1.31.
Zotero 插件